Columbia Gears Up To Handle Genotyping Data for Serious Adverse Events Consortium | GenomeWeb
The newly-launched Serious Adverse Events Consortium has tapped a research group at Columbia University to do data analysis for a large-scale project to identify genetic markers that might identify patients at high risk for adverse reactions to particular drugs.
The amount of the grant award to fund Columbia’s data coordination center is confidential, said Andrea Califano, a professor in the Joint Centers for Systems Biology at Columbia University who is helping oversee the project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.